Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VISTA-targeted CAR T-cells
- Development stage
- Preclinical
- Lead developer
- University of Minnesota
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VISTA-targeted CAR T-cells are chimeric antigen receptor (CAR) T-cell therapies engineered to target V-domain Ig suppressor of T cell activation (VISTA), an immune checkpoint regulator highly expressed on myeloid tumor cells and upregulated in certain malignancies such as malignant mesothelioma and acute myeloid leukemia (AML). By targeting VISTA, these CAR T-cells aim to overcome VISTA-mediated immunosuppression and selectively eliminate VISTA-expressing tumor cells. Preclinical studies, including those conducted at the University of Minnesota, have demonstrated the potential efficacy of VISTA-targeted CAR T-cells in inducing cytotoxicity against malignant mesothelioma and AML cell lines.
- Other names
- VISTA CAR T-cellsVISTA CAR-TVISTA-targeted CAR-T cells
02
Targets
PSGL-1 (P-selectin glycoprotein ligand-1)VISTA
Beyond the preview
Go deeper on VISTA-targeted CAR T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VISTA-targeted CAR T-cells.